Free Trial
NASDAQ:MOLN

Molecular Partners (MOLN) Stock Price, News & Analysis

Molecular Partners logo
$3.56 -0.09 (-2.47%)
Closing price 03:59 PM Eastern
Extended Trading
$3.52 -0.04 (-1.12%)
As of 04:04 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About Molecular Partners Stock (NASDAQ:MOLN)

Key Stats

Today's Range
$3.51
$3.64
50-Day Range
$3.54
$4.28
52-Week Range
$3.36
$12.70
Volume
1,273 shs
Average Volume
20,229 shs
Market Capitalization
$143.74 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$12.00
Consensus Rating
Strong Buy

Company Overview

Molecular Partners AG, a clinical-stage biotechnology company, develops designed ankyrin repeat proteins therapeutics for the treatment of oncology and virology diseases in Switzerland. The company develops MP0317, a CD40 agonist designed to activate immune cells within the tumor microenvironment by anchoring to fibroblast activation protein that is in Phase I clinical trial; and MP0533, a novel tetra-specific T cell-engaging DARPin for acute myeloid leukemia. It also develops Switch-DARPin platform, a multispecific cKIT x CD16a x CD47 Switch-DARPin program for targeted and conditional immune cell activation; and Radio-DARPin Therapy (RDT) platform, a delivery system for effective and selective delivery of radioactive payloads to solid tumors. It has license and research collaboration agreements with Novartis Pharma AG to develop DARPin-conjugated radioligand therapies; and collaboration agreement with Orano Med SAS to develop novel Radio-DARPin therapeutics. Molecular Partners AG was incorporated in 2004 and is headquartered in Schlieren, Switzerland.

Molecular Partners Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
48th Percentile Overall Score

MOLN MarketRank™: 

Molecular Partners scored higher than 48% of companies evaluated by MarketBeat, and ranked 606th out of 939 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Molecular Partners has received a consensus rating of Strong Buy. The company's average rating score is 3.50, and is based on 1 buy rating, no hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Molecular Partners has only been the subject of 1 research reports in the past 90 days.

  • Read more about Molecular Partners' stock forecast and price target.
  • Earnings Growth

    Earnings for Molecular Partners are expected to decrease in the coming year, from ($1.93) to ($2.08) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Molecular Partners is -1.66, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Molecular Partners is -1.66, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Molecular Partners has a P/B Ratio of 0.66. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

  • Percentage of Shares Shorted

    0.13% of the float of Molecular Partners has been sold short.
  • Short Interest Ratio / Days to Cover

    Molecular Partners has a short interest ratio ("days to cover") of 4.4.
  • Change versus previous month

    Short interest in Molecular Partners has recently decreased by 9.77%, indicating that investor sentiment is improving significantly.
  • Dividend Yield

    Molecular Partners does not currently pay a dividend.

  • Dividend Growth

    Molecular Partners does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    0.13% of the float of Molecular Partners has been sold short.
  • Short Interest Ratio / Days to Cover

    Molecular Partners has a short interest ratio ("days to cover") of 4.4.
  • Change versus previous month

    Short interest in Molecular Partners has recently decreased by 9.77%, indicating that investor sentiment is improving significantly.
    • Insider Buying vs. Insider Selling

      In the past three months, Molecular Partners insiders have not sold or bought any company stock.

    • Percentage Held by Insiders

      Only 5.93% of the stock of Molecular Partners is held by insiders.

    • Percentage Held by Institutions

      Only 26.55% of the stock of Molecular Partners is held by institutions.

    • Read more about Molecular Partners' insider trading history.
    Receive MOLN Stock News and Ratings via Email

    Sign-up to receive the latest news and ratings for Molecular Partners and its competitors with MarketBeat's FREE daily newsletter.

    MOLN Stock News Headlines

    Your Bank Account Is No Longer Safe
    What If Washington Declared That: YOUR Money ISN'T Actually Yours? Sounds insane, but that's exactly what the Department of Justice just admitted in court—claiming cash isn't legally your property. What does that mean? It means Washington thinks they can seize, freeze, or drain your accounts—whenever they want.
    See More Headlines

    MOLN Stock Analysis - Frequently Asked Questions

    Molecular Partners' stock was trading at $4.75 at the beginning of the year. Since then, MOLN stock has decreased by 25.1% and is now trading at $3.56.
    View the best growth stocks for 2025 here
    .

    Molecular Partners AG (NASDAQ:MOLN) posted its quarterly earnings data on Thursday, May, 15th. The company reported ($0.50) EPS for the quarter, missing the consensus estimate of ($0.39) by $0.11. Molecular Partners had a negative trailing twelve-month return on equity of 39.31% and a negative net margin of 1,043.01%.

    Molecular Partners (MOLN) raised $81 million in an IPO on Wednesday, June 16th 2021. The company issued 3,000,000 shares at a price of $27.14 per share. J.P. Morgan, SVB Leerink, Cowen and RBC Capital Markets acted as the underwriters for the IPO and Kempen & Co. was co-manager.

    Shares of MOLN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

    Based on aggregate information from My MarketBeat watchlists, some other companies that Molecular Partners investors own include PayPal (PYPL), Pfizer (PFE), NVIDIA (NVDA), Advanced Micro Devices (AMD), Robinhood Markets (HOOD), Taiwan Semiconductor Manufacturing (TSM) and Adobe (ADBE).

    Company Calendar

    Last Earnings
    5/15/2025
    Today
    6/05/2025
    Fiscal Year End
    12/31/2025

    Industry, Sector and Symbol

    Stock Exchange
    NASDAQ
    Sector
    Medical
    Industry
    Biological products, except diagnostic
    Sub-Industry
    Pharmaceutical Products
    Current Symbol
    NASDAQ:MOLN
    Fax
    N/A
    Employees
    180
    Year Founded
    N/A

    Price Target and Rating

    Average Stock Price Target
    $12.00
    High Stock Price Target
    $12.00
    Low Stock Price Target
    $12.00
    Potential Upside/Downside
    +232.4%
    Consensus Rating
    Strong Buy
    Rating Score (0-4)
    3.50
    Research Coverage
    2 Analysts

    Profitability

    Trailing P/E Ratio
    N/A
    Forward P/E Ratio
    N/A
    P/E Growth
    N/A
    Net Income
    -$69.04 million
    Net Margins
    -1,043.01%
    Pretax Margin
    -1,043.08%

    Debt

    Sales & Book Value

    Annual Sales
    $2.23 million
    Price / Cash Flow
    N/A
    Book Value
    $5.41 per share
    Price / Book
    0.67

    Miscellaneous

    Free Float
    37,969,000
    Market Cap
    $145.75 million
    Optionable
    Not Optionable
    Beta
    1.15
    Beginner's Guide To Retirement Stocks Cover

    Enter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.

    Get This Free Report

    This page (NASDAQ:MOLN) was last updated on 6/5/2025 by MarketBeat.com Staff
    From Our Partners